title: Interaction of fibroblast growth factor (FGF) with megakaryocytopoiesis and demonstration of FGF receptor expression in megakaryocytes and megakaryocytic-like cells.
abstract: We have investigated the interaction of fibroblast growth factor (FGF) with megakaryocytopoiesis. Acidic FGF (aFGF) stimulated the proliferation of murine megakaryocytes and human erythroleukemia (HEL) cells in a concentration-dependent manner. The concentrations of aFGF required to elicit half-maximum and maximum effects were similar for HEL and megakaryocytic colony formation. The effect of aFGF was comparable to that of basic FGF (bFGF) in both cell types. The effect of both FGFs was found to be synergistic with interleukin-3 (IL-3), and was abrogated by a monoclonal anti-IL-6 antibody. A specific cell surface receptor complex of approximately 120 Kd was detected for FGF by crosslinking experiments on HEL cells and total bone marrow (BM) cells. Single-cell autoradiography of megakaryocytes in BM smears and BM cultures showed binding sites for 125I-aFGF. Northern blot analysis of messenger RNA (mRNA) from total BM and HEL cells showed a 4.4-kb mRNA specific for FGF receptors type 1 (flg) and type 2 (bek). This was confirmed by polymerase chain reaction, which also showed the presence of FGF receptor mRNA in megakaryocytic-like cells, normal megakaryocytes, and platelets. Together, these results indicate that FGF is involved in megakaryocytopoiesis and suggest that this interaction may be mediated via FGF receptor type 1 and type 2 located on the megakaryocytic lineage or on accessory cells responsible for the release of megakaryocytic growth-promoting activities.
authors.affiliation: INSERM U 118, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Bikfalvi
authors.forename: Z C
authors.initials: ZC
authors.lastname: Han
authors.forename: G
authors.initials: G
authors.lastname: Fuhrmann
mesh_terms: D000818:Animals; D001483:Base Sequence; D015152:Blotting, Northern; D001854:Bone Marrow Cells; D002455:Cell Division; D002460:Cell Line; D004357:Drug Synergism; D016220:Fibroblast Growth Factor 1 / Q000494:pharmacology*; D000091344:Filaggrin Proteins; D015870:Gene Expression; D006410:Hematopoiesis / Q000502:physiology*; D006801:Humans; D007377:Interleukin-3 / Q000494:pharmacology; D015850:Interleukin-6 / Q000502:physiology; D004915:Leukemia, Erythroblastic, Acute; D008533:Megakaryocytes / Q000502:physiology*; D051379:Mice; D008969:Molecular Sequence Data; D012333:RNA, Messenger / Q000032:analysis; D017468:Receptors, Fibroblast Growth Factor / Q000235:genetics* / Q000502:physiology; D014407:Tumor Cells, Cultured
chemical_list: C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007377:Interleukin-3; D015850:Interleukin-6; D012333:RNA, Messenger; D017468:Receptors, Fibroblast Growth Factor; D016220:Fibroblast Growth Factor 1